BofA/Merrill Lynch Downgrades Pacira Pharmaceuticals (PCRX) to Neutral
Tweet
Share
E-mailGet Alerts PCRX Hot Sheet
Price: $22.71 +1.70%
Rating Summary:
11 Buy, 16 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 1 | Down: 2 | New: 2
Rating Summary:
11 Buy, 16 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 1 | Down: 2 | New: 2
Join SI Premium – FREE
BofA/Merrill Lynch downgraded Pacira Pharmaceuticals (NASDAQ: PCRX) from Buy to Neutral.
For an analyst ratings summary and ratings history on Pacira Pharmaceuticals click here. For more ratings news on Pacira Pharmaceuticals click here.
Shares of Pacira Pharmaceuticals closed at $91.11 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Morgan Stanley Downgrades BioMerieux (BIM:FP) (BMXMF) to Underweight
- JPMorgan Downgrades KFin Technologies Ltd (KFINTECH:IN) to Neutral
- Morgan Stanley Upgrades Demant A/S (DEMANT:DC) (WILYY) to Overweight
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
